Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)

Murakami T.; Abe M.; Tiksnadi A.; Nemoto A.; Futamura M.; Yamakuni R.; Kubo H.; Kobayashi N.; Ito H.; Hanajima R.; Hashimoto Y.; Ugawa Y.
Murakami, Takenobu (8338216800); Abe, Mitsunari (7404123222); Tiksnadi, Amanda (57204616263); Nemoto, Ayaka (57191277352); Futamura, Miyako (56513608000); Yamakuni, Ryo (57218920456); Kubo, Hitoshi (7402808606); Kobayashi, Naoto (58812488900); Ito, Hiroshi (7407939846); Hanajima, Ritsuko (7004551024); Hashimoto, Yasuhiro (56397195500); Ugawa, Yoshikazu (7005460744)
8338216800; 7404123222; 57204616263; 57191277352; 56513608000; 57218920456; 7402808606; 58812488900; 7407939846; 7004551024; 56397195500; 7005460744
Abnormal motor cortical plasticity as a useful neurophysiological biomarker for Alzheimer's disease pathology
2024
Clinical Neurophysiology
158
170
179
9
0
Department of Neurology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Nishimachi 36-1, Yonago, 683-8504, Japan; Center for Neurological Disorders, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Department of Neurology, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Salemba Raya No. 6, Jakarta, 10430, Indonesia; Advanced Clinical Research Center, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Rehabilitation Center, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Department of Radiology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Department of Radiological Sciences, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Azuma Street Clinic, Sakaemachi 1-28, Fukushima, 960-8031, Japan; Department of Biochemistry, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Department of Human Neurophysiology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan
Murakami T., Department of Neurology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan, Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Nishimachi 36-1, Yonago, 683-8504, Japan; Abe M., Center for Neurological Disorders, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Tiksnadi A., Department of Neurology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan, Department of Neurology, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Salemba Raya No. 6, Jakarta, 10430, Indonesia; Nemoto A., Advanced Clinical Research Center, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Futamura M., Rehabilitation Center, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Yamakuni R., Department of Radiology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Kubo H., Advanced Clinical Research Center, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan, Department of Radiological Sciences, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Kobayashi N., Azuma Street Clinic, Sakaemachi 1-28, Fukushima, 960-8031, Japan; Ito H., Advanced Clinical Research Center, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan, Department of Radiology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Hanajima R., Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Nishimachi 36-1, Yonago, 683-8504, Japan; Hashimoto Y., Department of Biochemistry, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan; Ugawa Y., Department of Neurology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan, Department of Human Neurophysiology, Faculty of Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan
Objective: Amyloid-beta (Aβ) and tau accumulations impair long-term potentiation (LTP) induction in animal hippocampi. We investigated relationships between motor-cortical plasticity and biomarkers for Alzheimer's disease (AD) diagnosis in subjects with cognitive decline. Methods: Twenty-six consecutive subjects who complained of memory problems participated in this study. We applied transcranial quadripuse stimulation with an interstimulus interval of 5 ms (QPS5) to induce LTP-like plasticity. Motor-evoked potentials were recorded from the right first-dorsal interosseous muscle before and after QPS5. Cognitive functions, Aβ42 and tau levels in the cerebrospinal fluid (CSF) were measured. Amyloid positron-emission tomography (PET) with 11C-Pittsburg compound-B was also conducted. We studied correlations of QPS5-induced plasticity with cognitive functions or AD-related biomarkers. Results: QPS5-induced LTP-like plasticity positively correlated with cognitive scores. The degree of LTP-like plasticity negatively correlated with levels of CSF-tau, and the amount of amyloid-PET accumulation at the precuneus, and correlated with the CSF-Aβ42 level positively. In the amyloid-PET positive subjects, non-responder rate of QPS5 was higher than the CSF-tau positive rate. Conclusions: Findings suggest that QPS5-induced LTP-like plasticity is a functional biomarker of AD. QPS5 could detect abnormality at earlier stages than CSF-tau in the amyloid-PET positive subjects. Significance: Assessing motor-cortical plasticity could be a useful neurophysiological biomarker for AD pathology. © 2024 International Federation of Clinical Neurophysiology
Alzheimer's disease; Amyloid beta; Long-term potentiation; Quadripulse stimulation; Synaptic plasticity; Tau; Transcranial magnetic stimulation
Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Humans; Long-Term Potentiation; Positron-Emission Tomography; tau Proteins; amyloid beta protein[1-42]; biological marker; tau protein; amyloid beta protein; biological marker; tau protein; aged; Alzheimer disease; Article; cerebrospinal fluid analysis; clinical article; cognition; controlled study; female; human; male; motor evoked potential; nerve cell plasticity; neurophysiology; positron emission tomography; stimulation; cerebrospinal fluid; cognitive defect; diagnostic imaging; long term potentiation; pathology; physiology
Ministry of Education, Culture, Sports, Science and Technology, MEXT, (15H01563, 15H05881, 16H05322, 17K09809, 19H01091, 20K07866, 22390181, 23H00495, 25293206)
This work was supported in part by a grant to T.M. from the Grant-in-Aid for Scientific Research project of the Ministry of Education, Culture, Sports, Science and Technology (Grant 15H01563 ), and grants to Y.U. (Grants 22390181 , 25293206 , 15H05881 , 16H05322 , 17K09809 , 19H01091 , 20K07866 , and 23H00495 ).
Elsevier Ireland Ltd
13882457
38219406
Article
Q1
1212
3032